Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Halozyme Therapeutics reported a record second quarter 2025, with total revenue up 41% to $326 million and royalty revenue surging 65% year-over-year to $206 million, driven by robust performance from its blockbuster subcutaneous therapies DARZALEX, Phesgo, and VYVGART Hytrulo. This strong momentum, bolstered by 11 recently realized growth catalysts including new product approvals and expanded indications for its ENHANZE technology, led the company to raise its full-year 2025 guidance for the second time, now projecting total revenue of $1.275 billion to $1.355 billion and royalty revenue of $825 million to $860 million. Halozyme also completed a $250 million share repurchase tranche and initiated another, while actively addressing ongoing IP litigation with Merck and advocating against potential negative impacts from IRA Part B guidance, maintaining a confident outlook for its long-term royalty streams.

Analysis

Halozyme Therapeutics delivered a record second quarter for 2025, characterized by accelerating, high-margin royalty growth that significantly outpaced overall revenue expansion. Total revenue increased 41% year-over-year to $326 million, propelled by a 65% surge in royalty revenue to $206 million. This performance was primarily driven by strong commercial execution for its three core subcutaneous blockbuster therapies: Johnson & Johnson's DARZALEX, which has achieved 96% subcutaneous conversion in the U.S.; Roche's Phesgo, with global conversion reaching 46%; and argenx's VYVGART Hytrulo, which saw total brand sales grow 97% year-over-year. The launch of VYVGART's pre-filled syringe has been a notable catalyst, attracting new patients and prescribers. This momentum prompted management to raise full-year 2025 guidance for the second time, now projecting total revenue of $1.275 billion to $1.355 billion and royalty revenue of $825 million to $860 million. The company is actively managing its capital, initiating a third $250 million share repurchase tranche, while navigating two key overhangs: ongoing patent litigation with Merck, with initial patent review decisions expected in mid-2026, and regulatory uncertainty surrounding the IRA Part B guidance, which management is actively lobbying against.

Key Decisions for Investors

• Given the second significant guidance upgrade driven by accelerating high-margin royalty streams, investors should re-evaluate Halozyme's valuation in the context of its enhanced growth trajectory and the potential to achieve its $1 billion royalty target ahead of the 2027 schedule.
• Monitor the commercial uptake of recently launched products like OCREVUS ZUNOVO and OPDIVO Qvantig, as their adoption rates, particularly new-to-brand patient starts, are key indicators for the next wave of royalty growth expected to become meaningful in 2026.
• Closely track developments in the patent litigation with Merck, with key Post-Grant Review decisions expected by June 2026, and the final IRA Part B guidance anticipated in the fall, as these events represent the primary risks that could impact long-term royalty projections.
• Note the company's capital allocation strategy, which balances aggressive share repurchases with a stated appetite for M&A that could add new, long-duration revenue streams, while maintaining a disciplined approach to leverage, currently at 1.2x net debt to EBITDA.